$1.68 Billion is the total value of RTW INVESTMENTS, LP's 60 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZBH | New | Zimmer Biomet Hldgs Inc | $55,320,000 | – | 403,000 | +100.0% | 3.29% | – |
| BLU | New | Bellus Health Inc New | $26,856,000 | – | 4,178,156 | +100.0% | 1.60% | – |
| PODD | New | Insulet Corp | $18,345,000 | – | 111,232 | +100.0% | 1.09% | – |
| MDXG | New | MiMedx Group Inc | $14,524,000 | – | 2,964,000 | +100.0% | 0.86% | – |
| CSTL | New | Castle Biosciences Inc | $13,478,000 | – | 745,045 | +100.0% | 0.80% | – |
| New | DermTech Inc | $12,498,000 | – | 2,386,871 | +100.0% | 0.74% | – | |
| QDEL | New | Quidel Corp | $10,828,000 | – | 176,495 | +100.0% | 0.64% | – |
| NTRA | New | Natera Inc | $9,429,000 | – | 287,470 | +100.0% | 0.56% | – |
| PTGX | New | Protagonist Therapeutics Inc | $9,155,000 | – | 762,283 | +100.0% | 0.54% | – |
| XGN | New | Exagen Inc | $7,925,000 | – | 511,633 | +100.0% | 0.47% | – |
| INMD | New | Inmode Ltd | $5,378,000 | – | 250,000 | +100.0% | 0.32% | – |
| SNSS | New | Sunesis Pharmaceuticals Inc | $5,000,000 | – | 6,946,074 | +100.0% | 0.30% | – |
| CLSD | New | Clearside Biomedical Inc | $2,361,000 | – | 3,747,699 | +100.0% | 0.14% | – |
| LVGO | New | Livongo Health Inc | $262,000 | – | 15,000 | +100.0% | 0.02% | – |
| TXG | New | 10x Genomics Inc | $252,000 | – | 5,000 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.